You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 10,888,605

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,888,605 protect, and when does it expire?

Patent 10,888,605 protects WEGOVY and is included in one NDA.

This patent has thirty-one patent family members in twenty-two countries.

Summary for Patent: 10,888,605

Patent landscape, scope, and claims:

Title:	GLP-1 compositions and uses thereof
Abstract:	The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
Inventor(s):	Moeller; Eva Horn (Alleroed, DK), Soerensen; Michael Duelund (Soeborg, DK), Lundqvist; Joakim (Malmoe, SE)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	16/774,666
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,888,605

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-001	Jun 4, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR WEIGHT MANAGEMENT	⤷ Subscribe
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR WEIGHT MANAGEMENT	⤷ Subscribe
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR WEIGHT MANAGEMENT	⤷ Subscribe
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR WEIGHT MANAGEMENT	⤷ Subscribe
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR WEIGHT MANAGEMENT	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,888,605

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	17187676	Aug 24, 2017

International Family Members for US Patent 10,888,605

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	112480	⤷ Subscribe
Australia	2018321157	⤷ Subscribe
Australia	2024204151	⤷ Subscribe
Brazil	112020002804	⤷ Subscribe
Canada	3082033	⤷ Subscribe
Chile	2020000422	⤷ Subscribe
Chile	2021001430	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.